[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640661":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Fytexia","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","DNF-10",[13],"Dietary Supplement: DNF-10: 250 mg\u002Fday",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","PLACEBO_COMPARATOR","Placebo",[19],"Other: Placebo: 250 mg maltodextrin\u002Fday",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","DNF-10: 250 mg\u002Fday",[9],null,{"type":27,"name":28,"description":17,"armGroupLabels":29,"otherNames":25},"OTHER","Placebo: 250 mg maltodextrin\u002Fday",[15],[31],{"facility":32,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Hospital Universitario HM Sanchinarro","RECRUITING","Madrid","28050","Spain","ES",{"type":39,"coordinates":40},"Point",[41,42],-3.70256,40.4165,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Ismael San Mauro Martín Dr.","CONTACT","+34617765977","info@grupocinusa.es",{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Domingo Carrera","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[56],{"name":57,"class":27},"Centros de Investigación de Nutrición y Salud","100640661","modulation-of-appetite-signaling-through-enterohormone-stimulation-by-dnf-10-100640661",false,"NCT07621393","Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10","Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10: Pilot Proof-of-concept, Crossover, Exploratory, Randomized, Double-blind, Placebo-controlled Study","DNF10-APET","Inclusion Criteria:\n\n* Healthy men and women aged 20 to 50 years.\n* Body Mass Index (BMI) of 18.5-24.9 kg\u002Fm² or 25.0-29.9 kg\u002Fm².\n* Stable use of permitted medications and\u002For dietary supplements during the study.\n* Individuals willing to maintain their usual dietary and physical activity habits throughout the study.\n* Subjects capable of understanding and complying with the study procedures.\n* Subjects who have signed the informed consent form.\n* Female participants must meet one of the following conditions:\n\n  1. Women with no potential for pregnancy, defined as women who have undergone surgical sterilization or who are postmenopausal.\n  2. Women of childbearing potential who use a highly effective contraceptive method (hormonal contraception, intrauterine device, condoms, male partner sterilization \\[vasectomy\\], or complete sexual abstinence) while participating in the study.\n\nExclusion Criteria:\n\n* Individuals with known eating behavior disorders (verified using the Spanish version of the Adult Eating Behavior Questionnaire, AEBQ).\n* Subjects with a body weight gain or loss ≥10% within the previous 3 months.\n* Treatment with medications or dietary supplements for weight loss, satiety, or glucose control.\n* Individuals consuming protein powders or dietary supplements related to the objectives of the study.\n* Participants receiving active treatment with GLP-1 receptor agonists or similar agents.\n* Participants taking medications or dietary supplements that, in the investigator's opinion, may interfere with the study objectives (e.g., affecting appetite), pose a safety risk, or confound the interpretation of the study results.\n* Depression or anxiety disorders that affect appetite.\n* High coffee consumption (more than 4 cups per day).\n* Smokers (more than 5 cigarettes per week), smoking during study assessment days, and\u002For drug abuse.\n* History of bariatric surgery within the last 3 years.\n* Low iron levels requiring treatment.\n* Individuals with renal or endocrine diseases (including diabetes).\n* Untreated or unstable hyperthyroidism, suicidal ideation, bipolar disorder, or evidence of any untreated or unstable neurological disorder.\n* Conditions or diseases that, in the investigator's judgment, may be worsened by participation in the study or may jeopardize the conduct of the study.\n* Presence of infectious diseases at the time of study inclusion (participants may be included 1 month after resolution of the illness).\n* Severely immunocompromised participants (transplant recipients, individuals treated with anti-rejection medications or steroids within the previous 30 days, or those who have received chemotherapy or radiotherapy within the last year).\n* Presence of active malignancy or any concomitant end-stage organ disease within the last 12 months that, in the investigator's judgment, contraindicates participation in the study.\n* Hypersensitivity, allergy, or intolerance to any of the components of the study product or standardized study menus (e.g., cow's milk protein allergy \\[CMPA\\], celiac disease, or non-celiac gluten intolerance).\n* Current participation or participation in another clinical trial within the previous three months.\n* Pregnant or breastfeeding women, women seeking pregnancy, or women of childbearing potential who are unwilling to use an effective contraceptive method.",true,"ALL","20 Years","50 Years",{"count":71,"type":72},50,"ESTIMATED","INTERVENTIONAL",[75],"NA","This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg\u002Fm². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.",[78],"Healthy Adult","2026-06-02",{"date":81,"type":82},"2026-06-04","ACTUAL",{"date":84,"type":82},"2026-05-12",{"date":86,"type":72},"2026-09",{"name":5,"class":6},1]